₹475.48 Crore Offer Opens for Bidding With a Long-Term Growth Story, but High Valuation, Regulatory Risks and Near-Term Profitability Pressures Require Caution
Sahajanand Medical Technologies’ ₹475.48 crore initial public offering (IPO) opened for subscription on Thursday, October 15, 2026. The issue has attracted attention because of the company’s position in the cardiovascular medical devices industry, its international presence and the potential for growth in advanced cardiac treatments. However, its valuation and near-term profitability outlook remain important considerations for investors.
The IPO is entirely an offer for sale (OFS), meaning the proceeds will go to the existing shareholders selling their stakes rather than directly to the company. Investors must therefore assess the offer primarily on the company’s business fundamentals, financial performance and valuation rather than expectations of fresh capital being raised for expansion.
Sahajanand Medical Technologies IPO: Key Details
The company has fixed the price band at ₹327–₹344 per share, with a lot size of 43 shares. At the upper end of the price band, a retail investor needs a minimum investment of ₹14,792, excluding applicable charges.
The subscription window runs from October 15 to October 19, 2026. The allotment is expected to be finalised on October 21, while the tentative listing date is October 23 on both the National Stock Exchange (NSE) and BSE.
As of 11:04 AM on October 15, the issue was subscribed 0.06 times, according to the BSE data cited in the original report. Qualified institutional buyers had not yet subscribed, the non-institutional investor category was subscribed 0.03 times, and the retail category stood at 0.10 times.
These figures represent an early snapshot and may change considerably before the issue closes. Subscription levels should be reviewed alongside the company’s financials and valuation rather than treated as a standalone indicator of investment quality.
Sahajanand Medical Technologies IPO GMP: What Does the Grey Market Indicate?
The grey market premium (GMP) was reported at ₹41 per share. Based on the upper issue price of ₹344, this implies an indicative grey-market price of ₹385.
The implied premium works out to approximately 11.92% over the upper price band.
However, GMP is an unofficial market indicator and is not a reliable guarantee of listing gains. It can fluctuate sharply during the subscription period and may not translate into the actual listing price. Investors should not base their decisions solely on grey-market quotations.
The actual listing performance will depend on overall market sentiment, investor demand, valuation expectations and the company's perceived growth prospects at the time of listing.
Business Overview: A Cardiovascular Devices Specialist
Established in 2001, Sahajanand Medical Technologies develops, manufactures and commercialises cardiovascular medical devices. Its portfolio spans two principal business segments: Vascular Intervention and Structural Heart.
Its products include drug-eluting stents, balloon catheters, transcatheter aortic valve implantation (TAVI) systems and occluders. These devices are used in the treatment of various cardiovascular conditions and represent specialised areas of medical technology.
The company has a presence in 77 countries and derives approximately 74% of its revenue from international markets, according to the brokerage assessment cited in the original report. This global footprint offers access to a broader customer base and creates opportunities to expand beyond India.
The company also operates research and development facilities in India and Thailand. Its intellectual property, clinical evidence and regulatory approvals across international markets may support product development and market access.
Nevertheless, international expansion in medical devices requires sustained spending on compliance, clinical validation, distribution and product development. Growth will depend on the company's ability to maintain approvals, compete effectively and convert its market presence into profitable sales.
IPO Valuation: Is the Issue Expensive?
At the upper price band, Anand Rathi valued Sahajanand Medical Technologies at approximately 50.6 times FY26 price-to-earnings (P/E) and 21.6 times FY26 enterprise value-to-EBITDA (EV/EBITDA). The implied post-issue market capitalisation was approximately ₹34,996 million, or ₹3,499.6 crore.
These valuation measures indicate that investors are being asked to pay a substantial multiple of the company's reported earnings. Such pricing places importance on the company's ability to sustain revenue growth, improve margins and strengthen profitability over the coming years.
A premium valuation may be justified if the company can expand its international business, introduce successful new products and improve operating efficiency. However, if earnings growth falls short of expectations, the stock could face valuation pressure after listing.
Investors should examine the company's revenue growth, net profit trends, operating margins, debt position, cash flows and return ratios before making a decision. Comparisons with listed medical-device companies can also help determine whether the IPO valuation offers a reasonable margin of safety.
Brokerage Review: Long-Term Growth Potential
Anand Rathi has recommended subscribing to the issue with a long-term investment horizon. Its assessment highlights the company's position in cardiovascular devices, established product portfolio, international reach and scope for future growth.
The brokerage believes the company's domestic market position in drug-eluting stents and diversified product range could support its longer-term prospects.
However, a positive long-term assessment does not eliminate the risks associated with the offer price. Investors need to consider whether the expected growth is already reflected in the valuation and whether the company can deliver consistent earnings improvement after listing.
Key Risks Investors Should Not Ignore
Regulatory dependence: Medical-device companies operate under strict regulatory frameworks. Delays in approvals, changes in compliance requirements or difficulties obtaining market access could affect product launches and revenue growth.
Pricing pressure: Price controls, competitive bidding and pressure from hospitals or distributors may restrict the company's ability to increase prices or protect margins.
Research and development spending: Developing new medical devices and generating supporting clinical evidence requires continued investment. These expenses may weigh on near-term profitability even when they create long-term opportunities.
International exposure: With a significant share of revenue generated outside India, the company is exposed to foreign-exchange movements, varying regulatory standards and market-specific competitive conditions.
Valuation risk: The reported FY26 P/E multiple of 50.6 times leaves limited room for disappointment if earnings growth or profitability improvement is slower than expected.
Offer-for-sale structure: Since the IPO is entirely an OFS, the proceeds go to selling shareholders. The issue does not directly provide fresh equity capital to fund the company's expansion plans.
What Should Investors Track Before Applying?
Investors should study the company's restated financial statements, revenue and profit growth, operating cash flows, debt, customer concentration and segment-wise performance. The sustainability of its international business and the contribution of newer products will also be important.
The final subscription figures can provide insight into demand from institutional, non-institutional and retail investors. However, strong subscription does not necessarily mean the issue is attractively valued, just as weak early demand does not automatically indicate poor long-term prospects.
Investors with a long investment horizon may focus on the company's competitive strengths and ability to generate consistent earnings. Those seeking quick listing gains should recognise that GMP is speculative and that actual listing performance may differ materially from grey-market expectations.
Market Outlook
Sahajanand Medical Technologies offers exposure to the specialised cardiovascular medical-device industry, supported by an established product portfolio, international operations and research capabilities. These factors provide a potential foundation for long-term expansion.
At the same time, the reported valuation is demanding, and regulatory requirements, pricing pressures, R&D expenditure and international-market risks could affect future profitability. The complete OFS structure also means that the IPO will not directly inject fresh funds into the business.
Anand Rathi's recommendation is to subscribe with a long-term perspective, but investors should independently evaluate the valuation and financial risks before applying. The reported GMP of ₹41 suggests potential listing upside, not a guaranteed return.
The key investment question is whether Sahajanand Medical Technologies can convert its global reach and product pipeline into sustained earnings growth strong enough to justify its IPO valuation. Investors should make their decision based on fundamentals, risk tolerance and investment horizon rather than GMP alone.